Treatment of rats with Jiangzhi Capsule improves liquid fructose-induced fatty liver: modulation of hepatic expression of SREBP-1c and DGAT-2

Journal of Translational Medicine

Yuhao Li⁵  Jianwei Wang¹  Robert Batey⁴  Yifan Yang⁵  Yongquan Pan³  Yuanyang Zhao² 

[1] Laboratory of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, China;Faculty of Basic Medical Sciences, Chongqing Medical University, Chongqing, China;The Laboratory Animal Center, Chongqing Medical University, Chongqing, China;Central Clinical School, Royal Prince Alfred Hospital, The University of Sydney, Sydney, NSW, Australia;Endocrinology and Metabolism Group, Sydney Institute of Health Sciences/Sydney Institute of Traditional Chinese Medicine, Sydney, NSW, Australia

关键词: Triglyceride;    Sterol regulatory element-binding protein-1c;    Liver;    Jiangzhi Capsule;    Lipid;    Acyl-coenzyme A:diacylglycerol acyltransferase;   

Others  :  1212312
DOI  :  10.1186/s12967-015-0529-6

 received in 2014-10-01, accepted in 2015-05-12,  发布年份 2015

【 摘 要 】

Background

Jiangzhi Capsule is an Australian listed patented traditional Chinese medicine and has been used for management of lipid abnormalities over the past 10 years. To obtain a better understanding regarding Jiangzhi Capsule, the present study investigated the effects and underlying mechanisms of Jiangzhi Capsule on chronic fructose overconsumption-induced lipid abnormalities.

Methods

Male rats were treated with liquid fructose in their drinking water over 14 weeks. Jiangzhi Capsule was co-administered (once daily, by oral gavage) during the last 7 weeks. Indexes of lipid and glucose homeostasis were determined enzymatically, by ELISA and/or histologically. Gene expression was analyzed by real-time PCR, Western blot and/or immunohistochemistry.

Results

Treatment with Jiangzhi Capsule (100 mg/kg) attenuated fructose-induced excessive triglyceride accumulation and Oil Red O-stained area in the liver. This effect was accompanied by amelioration of hyperinsulinemia. There was no significant difference in intakes of fructose and chow, and body weight between fructose control and fructose Jiangzhi Capsule-treated groups. Mechanistically, Jiangzhi Capsule downregulated fructose-stimulated hepatic overexpression of sterol regulatory element binding protein (SREBP)-1/1c at the mRNA and protein levels. Accordingly, the SREBP-1c downstream genes, acetyl-CoA carboxylase-1 and stearoyl-CoA desaturase-1, were also inhibited. In addition, acyl-coenzyme A:diacylglycerol acyltransferase (DGAT)-2 expression at the mRNA and protein levels in the liver was also inhibited after Jiangzhi Capsule treatment. In contrast, Jiangzhi Capsule affected neither carbohydrate response element binding protein, peroxisome proliferator-activated receptor (PPAR)-gamma and DGAT-1, nor PPAR-alpha and its target genes.

Conclusions

These findings demonstrate the anti-steatotic action of Jiangzhi Capsule in fructose-fed rats, and modulation of hepatic SREBP-1c and DGAT-2 involved in hepatic de novo synthesis of fatty acids and triglyceride, respectively. Our findings provide an evidence-based and mechanistic understanding of Jiangzhi Capsule supporting its application for the prevention and/or treatment of fatty liver and its associated disorders in clinical practice.

【 授权许可】

   
2015 Zhao et al.

【 图 表 】

Figure1.

Figure2.

Figure3.

Figure4.

Figure5.

Figure6.

Figure7.

Figure8.

【 参考文献 】

• [1]Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al.. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37:917-923.
• [2]Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008; 118:829-838.
• [3]Shi KQ, Fan YC, Liu WY, Li LF, Chen YP, Zheng MH. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Mol Biol Rep. 2012; 39:9715-9722.
• [4]Tappy L, Lê KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010; 90:23-46.
• [5]Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD et al.. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem. 2001; 276:38870-38876.
• [6]Yamazaki T, Sasaki E, Kakinuma C, Yano T, Miura S, Ezaki O. Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1. J Biol Chem. 2005; 280:21506-21514.
• [7]Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ et al.. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology. 2005; 42:362-371.
• [8]Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K et al.. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 2007; 282:22678-22688.
• [9]Hong X, Tang H, Wu L, Li L. Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease. J Pharm Pharmacol. 2006; 58:1391-1398.
• [10]Ji W, Gong BQ. Hypolipidemic activity and mechanism of purified herbal extract of Salvia miltiorrhiza in hyperlipidemic rats. J Ethnopharmacol. 2008; 119:291-298.
• [11]Chen J, Deng J, Zhang Y, Yang J, He Y, Fu W et al.. Lipid-lowering effects of Danhong injection on hyperlipidemia rats. J Ethnopharmacol. 2014; 154:437-442.
• [12]Yoshikawa M, Murakami T, Ueno T, Yashiro K, Hirokawa N, Murakami N et al.. Bioactive saponins and glycosides. VIII. Notoginseng (1): new dammarane-type triterpene oligoglycosides, notoginsenosides-A, -B, -C, and -D, from the dried root of Panax notoginseng (Burk.) F.H. Chen. Chem Pharm Bull. 1997; 45:1039-1045.
• [13]Ng TB. Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol. 2006; 58:1007-1019.
• [14]Ji W, Gong BQ. Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats. J Ethnopharmacol. 2007; 113:318-324.
• [15]Yim TK, Wu WK, Pak WF, Ko KM. Hepatoprotective action of an oleanolic acid-enriched extract of Ligustrum lucidum fruits is mediated through an enhancement on hepatic glutathione regeneration capacity in mice. Phytother Res. 2001; 15:589-592.
• [16]Kwon HJ, Kim YY, Choung SY. Amelioration effects of traditional Chinese medicine on alcohol-induced fatty liver. World J Gastroenterol. 2005; 11:5512-5516.
• [17]Zhang Y, Zhang L, Geng Y, Geng Y. Hawthorn fruit attenuates atherosclerosis by improving the hypolipidemic and antioxidant activities in apolipoprotein e-deficient mice. J Atheroscler Thromb. 2014; 21:119-128.
• [18]Tzeng TF, Lu HJ, Liou SS, Chang CJ, Liu IM. Emodin, a naturally occurring anthraquinone derivative, ameliorates dyslipidemia by activating AMP-activated protein kinase in high-fat-diet-fed rats. Evid Based Complement Altern Med. 2012; 2012:781812.
• [19]Liu C, Li Y, Zuo G, Xu W, Gao H, Yang Y et al.. Oleanolic acid diminishes liquid fructose-induced fatty liver in rats: role of modulation of hepatic sterol regulatory element-binding protein 1c-mediated expression of genes responsible for de novo fatty acid synthesis. Evid Based Complement Altern Med. 2013; 2013:534084.
• [20]Wang W, He Y, Lin P, Li Y, Sun R, Gu W et al.. In vitro effects of active components of Polygonum Multiflorum Radix on enzymes involved in the lipid metabolism. J Ethnopharmacol. 2014; 153:763-770.
• [21]Lin P, He YR, Lu JM, Li N, Wang WG, Gu W et al.. In vivo lipid regulation mechanism of Polygoni Multiflori Radix in high-fat dietfed rats. Evid Based Complement Altern Med. 2014; 2014:642058.
• [22]Dat NT, Cai XF, Rho MC, Lee HS, Bae K, Kim YH. The inhibition of diacylglycerol acyltransferase by terpenoids from Youngia koidzumiana. Arch Pharm Res. 2005; 28:164-168.
• [23]Ko JS, Ryu SY, Kim YS, Chung MY, Kang JS, Rho MC et al.. Inhibitory activity of diacylglycerol acyltransferase by tanshinones from the root of Salvia miltiorrhiza. Arch Pharm Res. 2002; 25:446-448.
• [24]Johnson RJ, Perez-Pozo SE, Sautin YY, Perez-Pozo SE, Sautin YY, Manitius J et al.. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Res. 2009; 30:96-116.
• [25]Gao H, Guan T, Li C, Zuo G, Yamahara J, Wang J et al.. Treatment with ginger ameliorates fructose-induced fatty liver and hypertriglyceridemia in rats: modulation of the hepatic carbohydrate response element binding protein-mediated pathway. Evid Based Complement Altern Med. 2012; 2012:570948.
• [26]Wang J, Gao H, Ke D, Zuo G, Yang Y, Yamahara J et al.. Improvement of liquid fructose-induced adipose tissue insulin resistance by ginger treatment in rats is associated with suppression of adipose macrophage-related pro-inflammatory cytokines. Evid Based Complement Altern Med. 2013; 2013:590376.
• [27]Li Y, Wang J, Gu T, Yamahara J, Li Y. Oleanolic acid supplement attenuates liquid fructose-induced adipose tissue insulin resistance through the insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt signaling pathway in rats. Toxicol Appl Pharmacol. 2014; 277:155-163.
• [28]Xing X, Li D, Chen D, Zhou L, Chonan R, Yamahara J et al.. Mangiferin treatment inhibits hepatic expression of acyl-coenzyme A:diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: a link to amelioration of fatty liver. Toxicol Appl Pharmacol. 2014; 280:207-215.
• [29]Rong X, Li Y, Ebihara K, Zhao M, Naowaboot J, Kusakabe T et al.. Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia. 2010; 53:1727-1731.
• [30]Wang BQ. Salvia miltiorrhiza: chemical and pharmacological review of a medicinal plant. J Med Plants Res. 2010; 4:2813-2820.
• [31]Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL et al.. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009; 119:1322-1334.
• [32]Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004; 10:355-361.
• [33]Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E et al.. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest. 2000; 106:1221-1228.
• [34]Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR et al.. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003; 278:34268-34276.
• [35]Chong MF, Fielding BA, Frayn KN. Mechanisms for the acute effect of fructose on postprandial lipemia. Asia Pac J Clin Nutr. 2007; 85:1511-1520.
• [36]Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard BK et al.. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 2007; 6:69-78.
• [37]Jornayvaz FR, Birkenfeld AL, Jurczak MJ, Kanda S, Guigni BA, Jiang DC et al.. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc Natl Acad Sci USA. 2011; 108:5748-5752.